Zai Lab Appoints Industry Leader Tao Fu as President & Chief Operating Officer, Expands US Presence - SC Read more about Zai Lab Appoints Industry Leader Tao Fu as President & Chief Operating Officer, Expands US Presence - SC
Zai Lab Presents Interim Results of its ongoing Phase 2 study of ZL-2301 (brivanib) in Chinese Patients with Advanced Hepatocellular Carcinoma (HCC) at the 21st Annual Meeting of the Chinese Society of Clinical Oncology - SC Read more about Zai Lab Presents Interim Results of its ongoing Phase 2 study of ZL-2301 (brivanib) in Chinese Patients with Advanced Hepatocellular Carcinoma (HCC) at the 21st Annual Meeting of the Chinese Society of Clinical Oncology - SC
Zai Lab Presents Results of its Pharmacokinetics (PK) Study for ZL-2306 (niraparib) in Chinese Ovarian Cancer Patients Showing Comparable Profile to non-Chinese Patients at the 21st Annual Meeting of the Chinese Society of Clinical Oncology - SC Read more about Zai Lab Presents Results of its Pharmacokinetics (PK) Study for ZL-2306 (niraparib) in Chinese Ovarian Cancer Patients Showing Comparable Profile to non-Chinese Patients at the 21st Annual Meeting of the Chinese Society of Clinical Oncology - SC
Zai Lab to Participate in the Leerink Rare Disease & Immuno-Oncology Roundtable - SC Read more about Zai Lab to Participate in the Leerink Rare Disease & Immuno-Oncology Roundtable - SC
Novocure 公司和再鼎医药就肿瘤电场治疗（TTF）在大中华区独家商业许可及全球战略开发合作达成协议 Read more about Novocure 公司和再鼎医药就肿瘤电场治疗（TTF）在大中华区独家商业许可及全球战略开发合作达成协议
Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China - SC Read more about Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China - SC
Zai Lab Announces Proposed Public Offering of American Depositary Shares - SC Read more about Zai Lab Announces Proposed Public Offering of American Depositary Shares - SC
Zai Lab Announces Financial Results and Corporate Progress for the Six Months ended June 30, 2018 - SC Read more about Zai Lab Announces Financial Results and Corporate Progress for the Six Months ended June 30, 2018 - SC
Zai Lab Doses First Patient in Phase III Trial of ZL-2306 (niraparib) in Patients with Small-Cell Lung Cancer in China - SC Read more about Zai Lab Doses First Patient in Phase III Trial of ZL-2306 (niraparib) in Patients with Small-Cell Lung Cancer in China - SC